Conferences

Emerging Data in Diffuse Large B-Cell Lymphoma

August 29th 2021

Experts discussed data from trials in lymphoma presented at ASCO 2021.

Novel Treatments for Hematologic Malignancies: Julie Vose, MD

July 31st 2021

The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed novel treatment options for patients with hematologic malignancies.

Benefits of CAR T Therapy in Follicular Lymphoma: Julie Vose, MD

July 29th 2021

The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed the benefits of CAR T-cell for patients with follicular lymphoma.

Tisagenlecleucel Efficacious, Durable in Relapsed/Refractory Follicular Lymphoma

July 28th 2021

Stephen J. Schuster, MD, discussed tisagenlecleucel's efficacy and safety over other available treatments for relapsed/refractory FL.

Mitigating Adverse Events in CAR T-Cell Therapy: Mounzer Agha, MD

July 19th 2021

The director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center discussed strategies to manage AEs associated with CAR T therapy.

Cilta-Cel Yields High Response Rates in R/R Multiple Myeloma: Saad Z. Usmani, MD, MBA, FACP

July 9th 2021

The director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute discussed overall response rate and stringent complete responses in the CARTITUDE-1 trial.

Setting a Foundation for CAR T-Cell Therapy: Mounzer Agha, MD

July 8th 2021

The director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center discussed how the meeting sets the foundation for what’s to come in the treatment of multiple myeloma and other hematologic malignancies.

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

June 27th 2021

The recommendation comes after positive data was released from the recent phase 2 KarMMa trial.

Promising Outlook in Multiple Myeloma with Cilta-Cel: Philippe Moreau, MD

June 26th 2021

Philippe Moreau, MD, discussed the CARTITUDE-1 trial's promising results with ciltacabtagene autoleucel read out at the 2021 ASCO Annual Meeting.

Safety Profile of Cilta-Cel: Saad Z. Usmani, MD, MBA, FACP

June 25th 2021

The director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute discussed adverse events in the CARTITUDE-1 trial.